



BioCryst to Present at Upcoming Investor Conferences

September 3, 2021

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](http://www.biocryst.com) (Nasdaq:BCRX) today announced that the company will present at the 2021 Virtual Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 1:20 p.m. ET and at the H.C. Wainwright 23rd Annual Global Investment Conference (virtual). The H.C. Wainwright presentation will be available on-demand in the Investors section of BioCryst's website starting at 7:00 a.m. ET on Monday, September 13, 2021.

Links to the live audio webcast of the Wells Fargo presentation and replays of both presentations may be accessed in the Investors section of BioCryst's website at <http://www.biocryst.com>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company's website at www.biocryst.com.

BCRXW

Investors:

John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:

Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com